Antigen detection
By using recombinant antibody target capture and detection steps in hepatitis B virus antigen detection, the problem of insufficient sensitivity in existing technologies is solved, enabling rapid and economical hepatitis B virus antigen detection suitable for samples from patients with early infection.
CN121336112APending Publication Date: 2026-01-13QBD QS IP
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202480035051.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-24
- Publication Date
- 2026-01-13
AI Technical Summary
Technical Problem
There is a lack of existing technologies that can accurately, rapidly, and cost-effectively detect hepatitis B virus infection, especially when the sensitivity is insufficient when detecting hepatitis B virus antigens.
Method used
An immunoassay method is employed that includes a target capture step and a target detection step. Recombinant antibodies are used in both the capture and detection steps. The recombinant antibodies bind to the target antigen in the sample, and the signal is detected by binding to the detectable portion.
Benefits of technology
It improves the sensitivity and specificity of detecting hepatitis B virus antigen, achieving rapid and economical detection results, and is suitable for testing samples from patients in the early stages of infection.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure provides an immunoassay method with very high sensitivity for detecting a target antigen in a sample. In one teaching, the capture and detection steps of these assay methods use recombinant antibodies. The disclosed immunoassay methods may be particularly suitable for the detection of HBV antigens.
Need to check novelty before this filing date? Find Prior Art